Karen Jacobson-Sive

Understanding Patient Perspectives Around Myasthenia Gravis Treatment May Help Optimize Care

Patients with myasthenia gravis (MG) often feel negative emotions around treatment, and considering patient preferences may help optimize and personalize treatment, and thereby improve patients’ overall well-being, according to a study that relied on patient focus groups and artificial intelligence […]

Understanding Patient Perspectives Around Myasthenia Gravis Treatment May Help Optimize Care Read More »

Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

Children with a genetic risk of developing myelodysplastic syndromes (MDS) and other hematopoietic malignancies (HM), such as leukemias and lymphomas, should receive intensive monitoring, in order to identify patients who would most benefit from hematopoietic stem cell transplantation (HSCT), according

Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition Read More »

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma

Rituximab-induced interstitial lung disease (RILD) in patients with non-Hodgkin lymphoma (NHL) presents most commonly as lung disease, organizing pneumonia, and nonspecific interstitial pneumonia, and it is associated with 179 pathogenic microorganisms, according to a retrospective study in the Annals of

Research Reveals Common Types of Rituximab-Induced Interstitial Lung Disease in Patients With Lymphoma Read More »

Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL

Zanubrutinib maintained long-term improved safety and tolerability profiles over a roughly 3.5 year period in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma, compared with ibrutinib, according to a randomized trial published in Blood.1 “In this study

Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL Read More »

Voretigene Neparvovec Helps Patients With RPE65-Related Retinopathy Regain Bilateral Function

The gene augmentation therapy voretigene neparvovec-rzyl (VN; Luxturna) helped patients with RPE65-related retinopathy partially regain the full‑field electroretinogram (ERG), according to a retrospective chart review of 12 patients in Documenta Ophthalmologica.1 “Voretigene neparvovec has changed the field of inherited retinal

Voretigene Neparvovec Helps Patients With RPE65-Related Retinopathy Regain Bilateral Function Read More »